SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to a recently announced $9.7 billion AI cloud services deal with Microsoft, which includes access to NVIDIA GPUs and a 20% prepayment. The community is highly bullish, discussing potential price targets and the significance of this deal in establishing IREN as a major player in AI infrastructure. Some investors believe that AI revenue will soon drive the stock, decoupling it from Bitcoin's volatility.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp sell-off possibly linked to news of a lawsuit against a former FDA official, which is creating uncertainty around the stock. The community is discussing the implications of this news, potential manipulation, and the company's upcoming earnings report. Some investors speculate about a buyout or partnership, while others express concern about the company's leadership and its impact on the stock's performance.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending as investors anticipate its earnings report, with debates raging about whether the stock is overvalued or poised for further gains. Bullish sentiment is fueled by Wedbush raising its price target and the company's involvement in the AI revolution, while bears cite its high P/E ratio. The community is closely watching for contract updates and guidance.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is gaining attention as traders discuss its potential for a significant price movement, drawing comparisons to other low-float stocks that have experienced substantial short squeezes. Community members are actively watching the stock, citing its low float and speculating about news catalysts. Some believe a coordinated effort from retail investors could lead to a squeeze comparable to previous high-profile situations.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as the community discusses its potential for growth, particularly regarding its QNX technology and partnerships with major tech companies. Some investors believe the current stock price undervalues the company's assets and future prospects, while others point to potential market manipulation and short-selling tactics affecting the stock's performance. The potential impact of government support and expansion in Asian markets are also being closely watched.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant stock movement following an unexpected shift in the FDA's stance on data requirements for its Huntington's disease therapy, AMT-130. The community is actively discussing the potential implications of this regulatory setback, with some speculating about a possible reversal of the decision or a buyout, while others assess the impact on the broader biotech sector. Discussions include the company's financial strategies, the possibility of a dead cat bounce, and the overall volatility and risk associated with biotech investments.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending following positive clinical data from its TERN-701 trial, selected for oral presentation at an upcoming hematology conference, driving speculation of a potential buyout. Community members are weighing the bullish data against a recent $300M shelf registration, debating short-squeeze potential versus dilution risks. The focus shifts to TERN's oncology program after the discontinuation of their GLP-1 candidate, with some viewing it as a streamlined path to acquisition.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as traders discuss whether it's setting up for a similar breakout to Amazon, focusing on accumulation patterns and potential FOMO. Some investors are frustrated with the stock's recent performance despite positive earnings, while others see it as an undervalued long-term play, especially with upcoming events like the World Cup and Olympics.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to a mix of factors, including news of a major cloud deal with IREN involving Nvidia chips and U.S. approval to export AI chips to the UAE, expanding MSFT's AI footprint. Community discussions revolve around the implications of increased capital expenditures on AI, OpenAI's potential IPO and revenue sharing, and whether the stock is currently undervalued despite strong earnings. Bullish sentiment emphasizes the cloud and AI synergy, while bears express concern over AI spending and potential market overvaluation.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending as investors discuss potential catalysts after a recent dip, including speculation around a stock split and potential acquisition of Warner Bros. Discovery assets. The community is weighing the impact of these factors against concerns about broader market conditions and specific challenges facing the company, like woke agenda pushing and subscriber losses. Some traders are seeing a buying opportunity, while others remain cautious.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apollomics shares fell 16% after-hours on Wednesday, even as the company said Nasdaq confirmed it remains in compliance with continued listing requirements, canceling a delisting appeal hearing.&nbsp;Trading in the company’s shares and warrants was halted on Sept. 17 for additional information.Reversal Of Wind-Up PlansThe update came as Apollomics continues to stabilize operations following financial challenges that nearly led to its shutdown. In August, the company announced plans to discontinue all clinical trial activities and wind up its business due to funding shortages.&nbsp;The company later reversed those plans in early September after receiving $4.1 million in PIPE investments and appointing a new management team led by CEO Hung-wen Chen, COO Yi-kuei Chen, and CFO Peter Lin.Focus On Late-Stage Oncology PipelineWith new funding and leadership, Apollomics said it is continuing its global Phase 2 SPARTA clinical trial for its lead drug candidate APL-101, a selective c-Met inhibitor for non-small cell lung cancer and other tumors with c-Met alterations.&nbsp;Apollomics said its lead cancer drug APL-101 has delivered encouraging results in more than 280 patients and remains at the center of its cancer research plans.The company added that its clinical trial partners have all been paid, and work is continuing without interruption. It has also implemented a 12-month plan to maintain its drug pipeline's momentum and ensure&nbsp;the company's financial stability during the next phase of development.Global Expansion PlansApollomics said it plans to leverage its existing China approvals for APL-101 in MET-amplified lung cancer and glioblastoma as a springboard for regulatory filings in Southeast Asia, the Middle East and other emerging markets.The company said it now has 12 employees and expects to have 15 employees by the end of October 2025. The company also expects to shift more roles from China to the U.S. and Taiwan to strengthen operations and ensure that its late-stage cancer drug programs remain on track.Stocktwits Traders Stay Upbeat Despite VolatilityOn Stocktwits, retail sentiment for Apollomics was ‘extremely bullish’ amid a 329% message volume.One user noted that the stock was in a very good position after being halted during the recent market pivot, while another highlighted the ongoing volatility in Apollomics shares.<stembedurl>https://stocktwits.com/Love_To_Learn/message/632496720</stembedurl><stembedurl>https://stocktwits.com/topstockalerts/message/632436028</stembedurl><a href="https://stocktwits.com/symbol/APLM">Apollomics’ stock</a> has doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Apollomics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Apollomics Stock Nosedived 16% After-Hours Today

The stock fell after-hours even after Nasdaq confirmed the biotech had regained compliance with listing standards.

Equity

Why Is Penny Stock Apollomics Trading Higher On Tuesday?

Apollomics shares soared after revealing promising Phase 2 SPARTA trial data for vebreltinib in non-CNS MET fusion solid tumors, showing a 43% ORR with notable responses in metastatic NSCLC...

Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CalciMedica (CALC Research Report), Apollomics (AP...

Apollomics price target lowered by $12 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript...

Apollomics reports FY23 EPS ($2.32) vs ($8.44) last year

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China...

Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 121.7% in February

Apollomics, Inc. (NASDAQ:APLM  Get Free Report) was the recipient of a large increase in short interest in February. As of February 29th, there was short interest totalling 43,900 shares, an...

Apollomics appoints Plunkett as CFO

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

Apollomics Inc - Ordinary Shares - Class A

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

APLM
Apollomics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest APLM News

APLMApollomics Inc - Ordinary Shares - Class A